Abstracts tagged "tophaceous gout"

Abstract Number: 358 • 2019 ACR/ARP Annual Meeting
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Meron Mezgebe¹, Megan Francis-Sedlak ¹, Brian LaMoreaux ¹ and Robert Holt ¹, ¹Horizon Therapeutics plc, Lake Forest, IL
Background/Purpose: From 2006 to 2012, gout was the primary indication for ~0.2% of all emergency department visits for adults, as reported in the Nationwide Emergency…
Abstract Number: 1183 • 2019 ACR/ARP Annual Meeting
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Michael Toprover¹, Anastasia Slobodnick ², Courtney Pike ³, Cheongeun Oh ⁴, Claudine Davis ², Michael Mechlin ⁵ and Michael H Pillinger ⁶, ¹Rheumatology Division, NYU Langone Health and Rheumatology Section, NY Harbor Health Care System, Department of Veterans Affairs., New York, NY, ²Rheumatology Division, NYU Langone Health, New York, ³Rheumatology Section, NY Harbor VA Healthcare System, New York, ⁴Biostatistics Department, NYU Langone Health, New York, ⁵Musculoskeletal Radiology, NYU Langone Health, New York, ⁶Rheumatology Division, NYU Langone Health and Rheumatology Section, NY Harbor Health Care System, Department of Veterans Affairs., New York
Background/Purpose: More than 130 cases of gout of the spine have been reported, with presenting symptoms including acute back pain, neuropathy, and spinal compression; diagnosis…
Abstract Number: 240 • 2015 ACR/ARHP Annual Meeting
Volumetric Assessment of Tophaceous Gout
Ralf G. Thiele¹, Laura Coates² and Darren Tabechian¹, ¹University of Rochester Medical Center, Rochester, NY, ²Medicine, University of Rochester, Rochester, NY
Background/Purpose: Ultrasound (US) can identify monosodium urate (MSU) tophi within joints, tendons, bursae and other soft tissues. The ability to readily, quickly and inexpensively assess…
Abstract Number: 1224 • 2014 ACR/ARHP Annual Meeting
Pegloticase for Tophus Debulking: Comparison of Dual Energy Computerized Tomography (DECT), Musculoskeletal Ultrasound (MSK-US) and Topographic Caliper Measurement for Assessing Debulking Rate
Dodji Modjinou¹, Elaine Karis², Soterios Gyftopoulos³, Jonathan Samuels⁴, Robert T. Keenan⁵, Daisy Bang⁶, Kristen Lee⁴, Svetlana Krasnokutsky-Samuels⁷, Daria B. Crittenden⁸ and Michael H. Pillinger⁸, ¹Internal Medicine/Rheumatology, NYU/HJD, New York, NY, ²pending, pending, NY, ³Radiology, NYU Langone Medical Center/NYU Hospital for Joint Diseases, New York, NY, ⁴Rheumatology, NYU Langone Medical Center, New York, NY, ⁵Rheumatology, Duke University, Durham, NC, ⁶Division of Rheumatology, NYU School of Medicine, New York, NY, ⁷Rheumatology, NYU School of Medicine, New York, NY, ⁸NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Pegloticase is approved for lowering serum urate (sUA) in chronic refractory tophaceous gout (CRTG), but the rate of tophus resolution is not well defined,…
Abstract Number: 118 • 2014 ACR/ARHP Annual Meeting
Difficult to Treat Gouty Arthritis Associated with Poor Health Related Quality of Life and High Resource Utilization: Post- Hoc Analysis
Louis Bessette¹, Frédéric Lioté², Carmen Moragues³, Rüdiger Moericke⁴, Zhang Zhiyi⁵, Alberto Ferreira⁶, Pascal Lecomte⁶, Sophia Kessabi⁶, Haijun Tian⁷ and Jasvinder A. Singh^8,9, ¹CHUL, Quebec, QC, Canada, ²Hôpital Lariboisière & University Paris Diderot, Paris, France, ³Hospital Platón, Barcelona, Italy, ⁴Institut für Präventive Medizin & Klinische Forschung GbR, Magdeburg, Germany, ⁵The First Affiliated Hospital of Haerbin Medical University, Haerbin, China, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Mayo Clinic, Rochester, MN, ⁹University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Difficult-to-treat (DTT) group in the MOTION study included symptomatic refractory gouty arthritis (RGA) patients with ≥3 flares, refractory to NSAIDs/colchicine/steroids or to uric acid…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.